What's Happening?
A recent study presented at the Endocrine Society's annual meeting in Chicago has found that individuals with obesity who are taking GLP-1 receptor agonists, such as Ozempic and Wegovy, tend to become less physically active. The research, led by Dr. Sajana
Maharjan of HSHS St. John's Hospital, analyzed data from the National Institutes of Health's All of Us Research Program, which included electronic health records and Fitbit activity data. The study involved 1,950 adults, with 753 participants providing sufficient wearable-device data for analysis. The findings showed a decline in daily step counts from 5,047 to 4,487 and a reduction in moderate-to-vigorous physical activity from 28 to 22 minutes per day. The decrease in physical activity was most pronounced in men and those experiencing joint or muscle pain.
Why It's Important?
The study challenges the common assumption that weight loss naturally leads to increased physical activity. This is significant because maintaining physical activity is crucial for preserving lean muscle mass, which is important for overall health and strength. The findings suggest that while GLP-1 receptor agonists are effective for weight loss, they may inadvertently lead to reduced physical activity, potentially impacting muscle health. This highlights the need for targeted interventions to encourage physical activity among individuals using these medications. The research underscores the importance of integrating exercise into weight loss programs to ensure comprehensive health benefits.
What's Next?
The study suggests that healthcare providers should emphasize the importance of physical activity for patients using GLP-1 receptor agonists. Future research may focus on developing specific interventions to promote exercise among this population. Additionally, there may be a need for public health campaigns to raise awareness about the importance of maintaining physical activity during weight loss treatments. Stakeholders, including medical professionals and pharmaceutical companies, might collaborate to create comprehensive treatment plans that combine medication with lifestyle modifications to optimize health outcomes.
